Association between cannabis use and blood pressure levels according to comorbidities and socioeconomic status
Waterreus, A. et al. Metabolic syndrome in people with a psychotic illness: Is cannabis protective?. Psychol. Med. 46, 1651–1662 (2016).
Vidot, D. C. et al. Metabolic syndrome among Marijuana users in the United States: An analysis of national health and nutrition examination survey data. Am. J. Med. 129, 173–179 (2016).
Schoeler, T. et al. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. Lancet Psychiatry 3, 947–953 (2016).
Thomas, G., Kloner, R. A. & Rezkalla, S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: What cardiologists need to know. Am. J. Cardiol. 113, 187–190 (2014).
Mittleman, M. A., Lewis, R. A., Maclure, M., Sherwood, J. B. & Muller, J. E. Triggering myocardial infarction by marijuana. Circulation 103, 2805–2809 (2001).
Wolff, V. et al. Cannabis-related stroke: Myth or reality?. Stroke 44, 558–563 (2013).
Jouanjus, E., Raymond, V., Lapeyre-Mestre, M. & Wolff, V. What is the current knowledge about the cardiovascular risk for users of cannabis-based products? A systematic review. Curr. Atheroscler. Rep. 19, 26 (2017).
Jouanjus, E., Lapeyre-Mestre, M., Micallef, J., French Association of the Regional Abuse and Dependence Monitoring Centres (CEIP-A) Working Group on Cannabis Complications. Cannabis use: Signal of increasing risk of serious cardiovascular disorders. J. Am. Heart Assoc. 3, e000638 (2014).
Reis, J. P. et al. Cumulative lifetime marijuana use and incident cardiovascular disease in middle age: The coronary artery risk development in young adults (CARDIA) study. Am. J. Public Health 107, 601–606 (2017).
Waterreus, A., Di Prinzio, P., Martin-Iverson, M. T. & Morgan, V. A. Sex differences in the cardiometabolic health of cannabis users with a psychotic illness. Drug Alcohol Depend. 194, 447–452 (2019).
Wetherington, C. L. Sex-gender differences in drug abuse: A shift in the burden of proof?. Exp. Clin. Psychopharmacol. 15, 411–417 (2007).
Park, J.-Y. & Wu, L.-T. Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review. Drug Alcohol Depend. 177, 1–13 (2017).
Whiting, P. F. et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA 313, 2456–2473 (2015).
Kjeldsen, S. E. Hypertension and cardiovascular risk: General aspects. Pharmacol. Res. 129, 95–99 (2018).
Alshaarawy, O. & Elbaz, H. A. Cannabis use and blood pressure levels: United States National Health and Nutrition Examination Survey, 2005–2012. J. Hypertens. 34, 1507–1512 (2016).
Bryson, E. O. & Frost, E. A. M. The perioperative implications of tobacco, marijuana, and other inhaled toxins. Int. Anesthesiol. Clin. 49, 103–118 (2011).
Jadoon, K. A., Tan, G. D. & O’Sullivan, S. E. A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI Insight 2, 93760 (2017).
Rosenkrantz, H. & Braude, M. Acute, subacute and 23-day chronic marihuana inhalation toxicities in the rat. Toxicol. Appl. Pharmacol. 28, 428–441 (1974).
Benowitz, N. L. & Jones, R. T. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin. Pharmacol. Ther. 18, 287–297 (1975).
Pacher, P., Bátkai, S. & Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58, 389–462 (2006).
Bátkai, S. et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110, 1996–2002 (2004).
Meier, M. H. et al. Associations between cannabis use and physical health problems in early midlife: A Longitudinal comparison of persistent cannabis vs tobacco users. JAMA Psychiat. 73, 731–740 (2016).
Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 12, e1001779 (2015).
Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203–209 (2018).
Goyal, H., Awad, H. H. & Ghali, J. K. Role of cannabis in cardiovascular disorders. J. Thorac. Dis. 9, 2079–2092 (2017).
Lev-Ran, S. et al. The association between cannabis use and depression: A systematic review and meta-analysis of longitudinal studies. Psychol. Med. 44, 797–810 (2014).
Davis, K. A. S. et al. Indicators of mental disorders in UK Biobank: A comparison of approaches. Int. J. Methods Psychiatr. Res. 28, e1796 (2019).
UK Biobank. Arterial Pulse-Wave Velocity. https://biobank.ndph.ox.ac.uk/ukb/ukb/docs/Pulsewave.pdf.
UK Biobank. UK Biobank Blood Pressure. https://biobank.ctsu.ox.ac.uk/crystal/docs/Bloodpressure.pdf.
Coleman, A., Freeman, P., Steel, S. & Shennan, A. Validation of the Omron 705IT (HEM-759-E) oscillometric blood pressure monitoring device according to the British Hypertension Society protocol. Blood Press. Monit. 11, 27–32 (2006).
Stang, A. et al. Algorithms for converting random-zero to automated oscillometric blood pressure values, and vice versa. Am. J. Epidemiol. 164, 85–94 (2006).
Said, M. A., Eppinga, R. N., Lipsic, E., Verweij, N. & van der Harst, P. Relationship of arterial stiffness index and pulse pressure with cardiovascular disease and mortality. J. Am. Heart Assoc. 7, e007621 (2018).
Badji, A., Cohen-Adad, J. & Girouard, H. Relationship between arterial stiffness index, pulse pressure, and magnetic resonance imaging markers of white matter integrity: A UK Biobank study. Front. Aging Neurosci. 14, 856782 (2022).
Vallée, A. Association between serum uric acid and arterial stiffness in a large-aged 40–70 years old population. J. Clin. Hypertens. 24, 885–897 (2022).
Vallée, A. Arterial stiffness nomogram identification by cluster analysis: A new approach of vascular phenotype modeling. J. Clin. Hypertens. Greenwich Conn https://doi.org/10.1111/jch.14571 (2022).
Williams, B. et al. 2018 practice guidelines for the management of arterial hypertension of the European society of hypertension and the European society of cardiology: ESH/ESC task force for the management of arterial hypertension. J. Hypertens. 36, 2284–2309 (2018).
UK Biobank. Biomarker assay quality procedures: Approaches used to minimise systematic and random errors (and the wider epidemiological implications). https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/biomarker_issues.pdf. (2019).
Chadeau-Hyam, M. et al. Education, biological ageing, all-cause and cause-specific mortality and morbidity: UK biobank cohort study. EClinicalMedicine 29–30, 100658 (2020).
Tyrrell, J. et al. Height, body mass index, and socioeconomic status: Mendelian randomisation study in UK Biobank. BMJ 352, i582 (2016).
Vallée, A. et al. Patterns of hypertension management in France in 2015: The ESTEBAN survey. J. Clin. Hypertens. Greenwich Conn https://doi.org/10.1111/jch.13834 (2020).
Matheson, J. et al. Sex differences in the acute effects of smoked cannabis: Evidence from a human laboratory study of young adults. Psychopharmacology 237, 305–316 (2020).
Wang, M. et al. The paradox association between smoking and blood pressure among half million Chinese people. Int. J. Environ. Res. Public. Health 17, E2824 (2020).
Thomas, D. C. Invited commentary: Is it time to retire the ‘pack-years’ variable? Maybe not!. Am. J. Epidemiol. 179, 299–302 (2014).
Penner, E. A., Buettner, H. & Mittleman, M. A. The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. Am. J. Med. 126, 583–589 (2013).
Strandberg, T. E. & Pitkala, K. What is the most important component of blood pressure: systolic, diastolic or pulse pressure?. Curr. Opin. Nephrol. Hypertens. 12, 293–297 (2003).
Williams, B., Lindholm, L. H. & Sever, P. Systolic pressure is all that matters. Lancet Lond. Engl. 371, 2219–2221 (2008).
Rodondi, N. et al. Marijuana use, diet, body mass index, and cardiovascular risk factors (from the CARDIA study). Am. J. Cardiol. 98, 478–484 (2006).
Niiranen, T. J., Kalesan, B., Mitchell, G. F. & Vasan, R. S. Relative contributions of pulse pressure and arterial stiffness to cardiovascular disease. Hypertension 73, 712–717 (2019).
Alshaarawy, O. & Anthony, J. C. Cannabis smoking and diabetes mellitus: Results from meta-analysis with eight independent replication samples. Epidemiol. Camb. Mass 26, 597–600 (2015).
Le Strat, Y. & Le Foll, B. Obesity and cannabis use: Results from 2 representative national surveys. Am. J. Epidemiol. 174, 929–933 (2011).
Costa, B. On the pharmacological properties of Delta9-tetrahydrocannabinol (THC). Chem. Biodivers. 4, 1664–1677 (2007).
Vallée, A., Lecarpentier, Y., Guillevin, R. & Vallée, J.-N. Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer’s disease. Acta Biochim. Biophys. Sin. 49, 853–866 (2017).
Stanley, C. P., Hind, W. H., Tufarelli, C. & O’Sullivan, S. E. Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation. Cardiovasc. Res. 107, 568–578 (2015).
Vandrey, R., Umbricht, A. & Strain, E. C. Increased blood pressure after abrupt cessation of daily cannabis use. J. Addict. Med. 5, 16–20 (2011).
Hartman, R. L. et al. Controlled cannabis vaporizer administration: Blood and plasma cannabinoids with and without alcohol. Clin. Chem. 61, 850–869 (2015).
Legrand, S.-A. et al. Alcohol and drugs in seriously injured drivers in six European countries. Drug Test. Anal. 5, 156–165 (2013).
Toennes, S. W. et al. Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. Anal. Bioanal. Chem. 400, 145–152 (2011).
Cooper, Z. D. & Craft, R. M. Sex-dependent effects of cannabis and cannabinoids: A translational perspective. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 43, 34–51 (2018).
Fogel, J. S., Kelly, T. H., Westgate, P. M. & Lile, J. A. Sex differences in the subjective effects of oral Δ9-THC in cannabis users. Pharmacol. Biochem. Behav. 152, 44–51 (2017).
Richiardi, L., Pizzi, C. & Pearce, N. Commentary: Representativeness is usually not necessary and often should be avoided. Int. J. Epidemiol. 42, 1018–1022 (2013).
Rothman, K. J., Gallacher, J. E. J. & Hatch, E. E. Why representativeness should be avoided. Int. J. Epidemiol. 42, 1012–1014 (2013).
Harrison, L. The validity of self-reported drug use in survey research: An overview and critique of research methods. NIDA Res. Monogr. 167, 17–36 (1997).